R&A PSYINS Announces Strategic Partnership with Nucleus to Provide the Psychedelic Industry Insurance Coverage
R&A PSYINS, an independent insurance broker that provides insurance to the psychedelic industry, announced a strategic partnership with
This landmark partnership was established to address a paramount issue facing psychedelic medicinal businesses. While more state legislators are pushing forward psychedelic policy reform – opening the door for more therapists and clinicians, retreats, and investors to enter the space – it is extremely difficult for psychedelic medicinal businesses to access insurance in this current hardened insurance market, leaving them exposed to a wide spectrum of risks.
Psychedelic therapies are in the highest risk pool for malpractice and other claims. Ketamine clinics, therapists and other practitioners need to understand, mitigate, and protect themselves from these perils. For companies that manufacture, test and distribute psychedelics for medicinal purposes, there are a host of additional risks, particularly if the goal is to go public. In response, R&A PSYINS developed a risk management program that offers specialty lines of business and medical malpractice insurance policies, including Professional Liability/Errors & Omissions, General Liability, Directors & Officers Liability, Product Liability, IP Defense/Enforcement, Cyber Defense/Data Breach and Workers’ Compensation coverage.
Nucleus, which is wholly owned by the venture capital firm, Iter Investments, is comprised of technology, data, and media assets intended to deliver intelligence, education, and opportunities to psychedelic industry stakeholders. The company’s acquisition of Psychedelic Invest and Neuly in 2022 was the foundation for its robust ecosystem. With its proprietary search technology, vast database, and suite of educational assets, Nucleus is helping to propel transformative health treatments forward.
“Both of our companies are at the forefront of the psychedelic medicinal movement,” said
This new partnership will benefit all stakeholders in Nucleus’ robust ecosystem by providing them access to psychedelic industry insurance that will ensure they are fully protected and in compliance with state and federal HIPPA regulations.
“We couldn’t be more excited to partner with a company like R&A PSYINS,” said
###
About R&A PSYINS
R&A PSYINS is a division of
+1 401-368-6655
[email protected]
Visit us on social media:
LinkedIn


Aspire General Insurance Appoints Byron Storms as CEO and Chairman
MetLife Named One of America’s Most Just Companies
Advisor News
- Why advisors should offer retirement-longevity planning
- A hybrid approach outperforms the 4% Rule, researchers find
- The missing piece in most retirement plans
- Clients are bringing TikTok insurance advice into advisor meetings
- Embracing a family-centric approach to financial planning
More Advisor NewsAnnuity News
- The Manhattan Life Insurance Company Acquires Union Security Life Insurance Company of New York
- Cayman Islands premier to meet with U.S. reinsurance regulators
- Investigation finds deceptive sales, churning of annuities targeting postal workers
- Corebridge annuity sales slip ahead of Equitable marriage
- California teachers settle class-action lawsuit over in-plan annuity fees
More Annuity NewsHealth/Employee Benefits News
Life Insurance News
- AM Best Affirms Credit Ratings of PT KB Insurance Indonesia
- Westaim Reports Q2 2026 Results for the Quarter Ended June 30, 2026 and Leadership Update for Ceres Life Insurance Company
- Bismarck man convicted of insurance fraud involving dead wife sentenced to prison
- Insurers, rating firms push back on NAIC credit rating oversight plan
- The Manhattan Life Insurance Company Acquires Union Security Life Insurance Company of New York
More Life Insurance News